With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
|Videos|August 28, 2020
What are Monoclonal Antibodies [mAb]? | John F. Kokai Kun, PhD
Author(s)Grant M. Gallagher
John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of monoclonal antibody treatment.
Advertisement
Synthesised in the laboratory, monoclonal antibodies or "mAbs" aim to mimic natural antibodies. These antibodies can be clinically beneficial in a number of ways, including but not limited to imitating a natural immune response.
The treatment has the potential to be given as a preventative option for people exposed to a virus, and to treat and prevent disease progression in patients already infected by a virus. But there are concerns about how well such a drug could scale.
John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia (USP), is well qualified to explain the fundamentals of monoclonal antibody treatment.
In this first part of our conversation, he introduces his work at USP and goes into the basic story of mAbs — from early discoveries in the 1970s to today.
When you look at a prescription in the United States, you're likely to see "USP" written on the bottle. The same goes for an increasing number of over-the-counter supplements, as vitamin manufacturers look to reassure potential patients in a crowded and opaque market.
Originally formed by a collective of doctors looking to ensure shared quality control, USP has grown into an institutional authority over the years.
Advertisement
Related to this article
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
Advertisement
Advertisement